Neok Bio received FDA IND clearance for NEOK‑001, a bispecific antibody‑drug conjugate, enabling a phase I solid tumor trial. Avacta also cleared an IND for AVA‑6103, a fibroblast activation protein (FAP)‑targeted exatecan peptide‑drug conjugate (PDC), moving both programs toward first‑in‑human dosing. Company statements and regulatory filings indicate clinical dosing is expected in the coming months for NEOK‑001 and AVA‑6103, with early data anticipated next year. Both assets use targeted payload delivery to widen the therapeutic window in solid tumors. What happened: Two oncology developers cleared critical regulatory milestones to open early‑phase trials for targeted cytotoxic conjugates. Sources: company press releases and industry coverage. Clinical note: bispecific ADCs and PDCs seek to marry selectivity with potent payloads to overcome solid tumor delivery challenges.